Cogent Biosciences, Inc. (COGT)

NASDAQ: COGT · IEX Real-Time Price · USD
7.77 -0.36 (-4.43%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap309.64M
Revenue (ttm)n/a
Net Income (ttm)-163.10M
Shares Out39.85M
EPS (ttm)-4.93
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume233,507
Open8.12
Previous Close8.13
Day's Range7.56 - 8.28
52-Week Range5.83 - 12.60
Betan/a
AnalystsStrong Buy
Price Target22.50 (+189.6%)
Earnings DateNov 8, 2021

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and ...

IndustryBiotechnology
IPO DateMar 29, 2018
Employees15
Stock ExchangeNASDAQ
Ticker SymbolCOGT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is 22.50, which is an increase of 189.58% from the latest price.

Price Target
$22.50
(189.58% upside)
Analyst Consensus: Strong Buy

News

Cogent Biosciences Provides 2022 Corporate Guidance

CAMBRIDGE, Mass. and BOULDER, Colo.

2 weeks ago - PRNewsWire

Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass. and BOULDER, Colo.

1 month ago - PRNewsWire

Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo.

2 months ago - PRNewsWire

Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo.

5 months ago - PRNewsWire

Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo.

6 months ago - PRNewsWire

Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo.

7 months ago - PRNewsWire

Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

CAMBRIDGE, Mass. and BOULDER, Colo.

8 months ago - PRNewsWire

Cogent Biosciences Announces Creation of Cogent Research Team

BOULDER, Colo. and CAMBRIDGE, Mass.

9 months ago - PRNewsWire

Cogent Biosciences, Inc. (COGT) Reports Q4 Loss, Lags Revenue Estimates

Cogent Biosciences, Inc. (COGT) delivered earnings and revenue surprises of -1910.00% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...

10 months ago - Zacks Investment Research

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announ...

10 months ago - PRNewsWire

Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors

CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

10 months ago - PRNewsWire

Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021

CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

11 months ago - PRNewsWire

Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021

CAMBRIDGE, Mass., Feb. 11, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

11 months ago - PRNewsWire

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Op...

CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, tod...

1 year ago - PRNewsWire

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announce...

1 year ago - PRNewsWire

Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock

CAMBRIDGE, Mass., Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

1 year ago - PRNewsWire

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference

CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

1 year ago - PRNewsWire

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

1 year ago - PRNewsWire

Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer

CAMBRIDGE, Mass., Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, to...

1 year ago - PRNewsWire

Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational P...

CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases, today a...

1 year ago - PRNewsWire